Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer

[1]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Yunyan Gu,et al.  Extensive up-regulation of gene expression in cancer: the normalised use of microarray data. , 2012, Molecular bioSystems.

[3]  Surajit Ray,et al.  Top scoring pairs for feature selection in machine learning and applications to cancer outcome prediction , 2011, BMC Bioinformatics.

[4]  L. Esserman,et al.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.

[5]  L. Wessels,et al.  Do predictive signatures really predict response to cancer chemotherapy? , 2010, Cell cycle.

[6]  Hongdong Li,et al.  Multi-level reproducibility of signature hubs in human interactome for breast cancer metastasis , 2010, BMC Systems Biology.

[7]  David M. Simcha,et al.  Tackling the widespread and critical impact of batch effects in high-throughput data , 2010, Nature Reviews Genetics.

[8]  Yuan Qi,et al.  Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer , 2010, Clinical Cancer Research.

[9]  Benjamin Haibe-Kains,et al.  Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. , 2010, The Lancet. Oncology.

[10]  C. Sotiriou,et al.  Genomic grade index is associated with response to chemotherapy in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Paul Dent,et al.  Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[12]  Hui Xiao,et al.  Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes , 2009, Bioinform..

[13]  Conly L. Rieder,et al.  Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied , 2008, The Journal of cell biology.

[14]  Jing Zhu,et al.  Apparently low reproducibility of true differential expression discoveries in microarray studies , 2008, Bioinform..

[15]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Janice N Cormier,et al.  Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Brenton,et al.  Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. , 2007, Cancer cell.

[19]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Xin Lu,et al.  ASPP: a new family of oncogenes and tumour suppressor genes , 2007, British Journal of Cancer.

[21]  J. Ross,et al.  Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Zhong,et al.  ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. , 2006, Genes & development.

[23]  Norman Wolmark,et al.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Roland Eils,et al.  Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Hortobagyi,et al.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Richard Simon,et al.  Bias in error estimation when using cross-validation for model selection , 2006, BMC Bioinformatics.

[27]  Manuela Gariboldi,et al.  Limits of predictive models using microarray data for breast cancer clinical treatment outcome. , 2005, Journal of the National Cancer Institute.

[28]  Daniel Q. Naiman,et al.  Simple decision rules for classifying human cancers from gene expression profiles , 2005, Bioinform..

[29]  Daniel Q. Naiman,et al.  Classifying Gene Expression Profiles from Pairwise mRNA Comparisons , 2004, Statistical applications in genetics and molecular biology.

[30]  Hans-Peter Sinn,et al.  International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[32]  Xin Lu,et al.  ASPP proteins specifically stimulate the apoptotic function of p53. , 2001, Molecular cell.

[33]  L. Naumovski,et al.  p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis , 2001, Oncogene.

[34]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[35]  S. Glück,et al.  Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657 , 2013 .

[36]  Maqc Consortium.  The MicroArray Quality Control ( MAQC )-II study of common practices for the development and validation of microarray-based predictive models , 2012 .

[37]  Susan E. Abbatiello,et al.  Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.

[38]  G. Hortobagyi,et al.  Prognostic value of initial clinical disease stage after achieving pathological complete response. , 2008, The oncologist.